Evaluation of the Antiproliferative Effect of Extract from Equisetum arvense L. on Hepatocellular Carcinoma SNU-449 Cells
Abstract
Equisetum arvense L. (Horsetail) extract (HTE) has been used traditionally in the treatment of various ailments. However, its potential as an anticancer agent, particularly in hepatocellular carcinoma (HCC), is still not well understood. The objective of this study is to investigate the anticancer potential of HTE in the SNU449 HCC cells. To assess the antiproliferative and migratory properties of HTE on HCC, a cell viability was analyzed at 24 and 48nd hours using seven different concentrations of HTE (ranging from 7.81 to 500 ppm). The lowest concentration that effectively affected cell viability was determined, and subsequent experiments were carried out using this dose at the 24-hour mark. The MTT, colony formation, wound healing, and Western blotting assays to measure CASP-3 and Cleaved CASP-3 expressions were also included in the analysis. The MTT assay identified 326 ppm as the minimum effective dose at the 24-hour time point. Colony formation assays showed a notable difference between treated and untreated cells, with a surviving fraction of 46.9% in HTE-treated cells. The wound healing assay indicated that HTE-treated cells exhibited a 43.4% wound closure rate after 24 hours. Western blot analysis revealed the normalized volume ratios for Caspase-3 were 53222328 in the treated cells, and 7948593 in the control, while for Cleaved Caspase-3, the ratios were 707454 in treated cells and 596409 in control cells. The results suggest that HTE has antiproliferative and migratory properties on SNU-449 HCC cells. Further investigations are required to understand the underlying mechanisms of these effects.
Keywords
Equisetum arvense L., Horsetail, Antiproliferative Effects, SNU-449 Cell Line
Project Number
Proje yok
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
- Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 2018;12:9–26.
- McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13.
- Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27:85–102.
- Yu LX, et al. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. npj Precision Oncology. 2018;2:6.
- Rayginia TP, Kizhakkeveettil CK, Shifana SC, Pellissery MJ, Abhishek A, John Anto R. Phytochemicals as potential lead molecules against hepatocellular carcinoma. Curr Med Chem. 2024;31(32):5199–5221.
- Dormousoglou M, Efthimiou I, Antonopoulou M, et al. Investigation of the genotoxic, antigenotoxic, and antioxidant profile of different extracts from Equisetum arvense L. Antioxidants. 2022;11(8):1393.
- Al-Fahad D, Al-Harbi B, Abbas Y, Al-Yaseen F. A comparative study to visualize PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in MDA-MB-231 breast cancer cell line. Rep Biochem Mol Biol. 2022;10(4):518-526.
- Sandhu NS, Kaur S, Chopra D. Pharmacognostic evaluation of Equisetum arvense Linn. Int J PharmTech Res. 2010;2:1460–1464.
- Choopani A, Fazilati M, Latifi AM, et al. An efficient method for extraction and enrichment of γ-linolenic acid (GLA) from Spirulina. Letters in Applied NanoBioScience. 2022;11(1):3166–3174.